Ligand insider files to sell 467 shares

Ligand Pharmaceuticals insider selling notice: A Form 144 reports a planned sale of 467 shares of Ligand common stock through UBS Financial Services Inc., with an aggregate market value of 89,748.06.

Rhea-AI Filing Summary

Ligand Pharmaceuticals insider selling notice: A Form 144 reports a planned sale of 467 shares of Ligand common stock through UBS Financial Services Inc., with an aggregate market value of 89,748.06. The shares are listed on Nasdaq, and 19,681,720 shares were outstanding at the time referenced.

The shares to be sold are common stock acquired on 04/24/2024 from the issuer in various transactions, totaling 467 shares. The filing also notes that John Kozarich has sold 467 common shares in each of three transactions over the past three months, with gross proceeds of 91,456.91, 89,219.00, and 88,532.51.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing for LGND disclose?

The Form 144 discloses a planned sale of 467 shares of Ligand Pharmaceuticals common stock. The shares have an aggregate market value of 89,748.06 and are expected to be sold on Nasdaq through UBS Financial Services Inc., subject to Rule 144 conditions.

How many LGND shares are planned to be sold and through which broker?

The notice covers a planned sale of 467 Ligand common shares. The transaction is designated to be executed through UBS Financial Services Inc. at its New York address, with the shares listed for trading on Nasdaq under the company’s existing common stock listing.

When were the LGND shares being sold under Form 144 acquired?

The 467 Ligand common shares covered by the Form 144 were acquired on 04/24/2024 from the issuer in various acquisition transactions. The filing identifies the issuer as the source and lists both the acquisition date and the payment date as 04/24/2024.

What prior LGND share sales by the filer are disclosed in the last 3 months?

The notice lists three prior sales by John Kozarich: 467 common shares on 11/03/2025, 467 shares on 12/01/2025, and 467 shares on 01/02/2026. Gross proceeds were 89,219.00, 91,456.91, and 88,532.51, respectively.

How many Ligand (LGND) shares were outstanding according to the filing?

The Form 144 indicates that 19,681,720 shares of Ligand common stock were outstanding at the referenced time. This figure provides context for the planned 467-share sale reported in the notice, which is processed under Rule 144 resale provisions.

On what date is the LGND Form 144 sale expected to occur?

The filing lists an approximate sale date of 02/02/2026 for the 467 Ligand common shares. This is the date on or around which the filer expects to execute the planned Rule 144 sale through the designated broker on Nasdaq.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/02/2026 - 04:12 PM EST Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001223000
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	LIGAND PHARMACEUTICALS INC
SEC File Number	001-33093
Address of Issuer	3911 SORRENTO VALLEY BLVD SUITE 110 SAN DIEGO CALIFORNIA 92121
Phone	858-550-7500
Name of Person for Whose Account the Securities are To Be Sold	KOZARICH JOHN W
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	UBS Financial Services, Inc. Eleven Madison Avenue 4th Floor New York NY 10010	467	89748.06	19681720	02/02/2026	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	04/24/2024	Various	Issuer			467	04/24/2024	NA

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
John Kozarich 3911 Sorrentino Valley Boulevard Suite 110 San Diego CA 92121	Common	12/01/2025	467	91456.91
John Kozarich 3911 Sorrentino Valley Blvd. Suite 110 San Diego CA 92121	Common	11/03/2025	467	89219.00
John Kozarich 3911 Sorrentino Valley Boulevard Suite 110 San Diego CA 92121	Common	01/02/2026	467	88532.51

144: Remarks and Signature

Remarks
Date of Notice	02/02/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	03/07/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ UBS Financial Services Inc, as attorney-in-fact for John Kozarich
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)